Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

NCT06171750 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Cutaneous Tumor
Subcutaneous Tumor
Malignant Solid Tumor
Solid Tumor
Metastatic Solid Tumor
Metastasis to Soft Tissue
Non Small Cell Lung Cancer
Cutaneous Squamous Cell Carcinoma

Interventions

DRUG: tolododekin alfa
DRUG: Cemiplimab

Sponsor

Ankyra Therapeutics, Inc